Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Comment by TimeScapeon Feb 14, 2014 11:11am
216 Views
Post# 22210129

RE:RE:RE:Gigantic move in the past 3 days

RE:RE:RE:Gigantic move in the past 3 daysYah, it almost joined my other great biotech investments, Vasogen, Hemosol, Synsorb, Isotechnika and a couple others I've long since forgotten. Fortunately, only put a small amount into each. The sector actually has actually gotten some life in Canada in the last couple of years. Did very well with Paladin Labs before the recent buyout. Cipher is an interesting company. Oncolytics is in Phase 3, finally. Of course Valiant has been on wheels. Recently bought and sold Novadaq for a nice gain. Patient Home Monitoring is another one that looks promising. Microbix had a very good earnings report this a.m. and is up about 10% on the news. They've got a couple of interesting product lines.
Bullboard Posts